Enavogliflozin

Phase 3Small molecule

Daewoong Pharmaceutical Co. LTD.

Enavogliflozin is one of 239 small molecule programs targeting Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

238

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetes MellitusActive, not recruiting

Tricuspid RegurgitationActive, not recruiting

Aortic Valve StenosisRecruiting

CardiomyopathyNot yet recruiting

Type 2 Diabetes MellitusRecruiting

AtherosclerosisRecruiting

Atrial FibrillationNot yet recruiting

Hypertrophic CardiomyopathyRecruiting

ObesityRecruiting

Diabetes MellitusPreclinical

Active, not recruiting

Tricuspid RegurgitationPhase 3

Active, not recruiting

Aortic Valve StenosisPhase 3

Recruiting

CardiomyopathyPhase 3

Not yet recruiting

Type 2 Diabetes MellitusPhase 3

Recruiting

AtherosclerosisPhase 3

Recruiting

Atrial FibrillationPhase 3

Not yet recruiting

Hypertrophic CardiomyopathyPhase 3

Recruiting

ObesityPhase 3

Recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Maridebart Cafraglutide

Amgen

Phase 3

7 2

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 3

1 3

NNC0487-0111

Novo Nordisk

Phase 3

11 4

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 5

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

1 6

Ribupatide

KKailera

Phase 3

3 7

Elecoglipron

AstraZeneca

Phase 3

1 8

PF-08653944

Pfizer

Phase 3

5 9

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

2 10

Avapro

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Hypertrophic Cardiomyopathy

NCT06580717

Post-ApprovalRecruiting

Atherosclerosis

NCT06399835

Q2 2027

Post-ApprovalNot yet recruiting

Cardiomyopathy

NCT07240844

Q3 2027

Phase 3Active, not recruiting

Tricuspid Regurgitation

NCT06027307

Q2 2029

ApprovedRecruiting

Aortic Valve Stenosis

NCT05672836

Clinical

Trials by Indication[1]

Obesity1 trial

Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity

Recruiting·KKorea University Anam Hospital·Phase 4·NCT06782139·30 enrolled

Diabetes Mellitus1 trial

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

Active, not recruiting· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.··NCT05926414·15,000 enrolled

Hypertrophic Cardiomyopathy1 trial

ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

Recruiting·YYonsei University·Phase 4·NCT06580717·200 enrolled

Cardiomyopathy1 trial

Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

Not yet recruiting·SSeoul St. Mary's Hospital·Phase 4·NCT07240844·68 enrolled

Type 2 Diabetes Mellitus1 trial

A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

Recruiting·YYonsei University·Phase 4·NCT06642623·2,862 enrolled

4 more indications

Atrial Fibrillation1 trial

Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

Not yet recruiting·YYonsei University·Phase 4·NCT06528262·390 enrolled

Atherosclerosis1 trial

Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting·SSeoul National University Bundang Hospital·Phase 4·NCT06399835·120 enrolled

Tricuspid Regurgitation1 trial

Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

Active, not recruiting·—·Phase 3·NCT06027307·541 enrolled

Aortic Valve Stenosis1 trial

A Randomized, Double-Blind, Placebo-controlled Trial to Evaluate Efficacy and Safety of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, Enavogliflozin Compared to Placebo on Reducing Major Cardiovascular Events or Worsening Heart Failure in Patients With Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement (TAVR) and With Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting·DDuk-Woo Park, MD·Approved·NCT05672836·1,040 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Enavogliflozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enavogliflozin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enavogliflozin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daewoong Pharmaceutical Co. LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Daewoong Pharmaceutical Co. LTD.

Enavogliflozin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q2 2029

Trials by Indication[1]

Obesity1 trial

Diabetes Mellitus1 trial

Hypertrophic Cardiomyopathy1 trial

Cardiomyopathy1 trial

Type 2 Diabetes Mellitus1 trial

Atrial Fibrillation1 trial

Atherosclerosis1 trial

Tricuspid Regurgitation1 trial

Aortic Valve Stenosis1 trial

References

Drug Info

Quick Facts

Related News